The human splice variant δ16HER2 induces rapid tumor onset in a reporter transgenic mouse

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Marchini, Cristina ^a   Gabrielli, Federico ^a   Iezzi, Manuela ^b   Zenobi, Santa ^a   Montani, Maura ^a   Pietrella, Lucia ^a   Kalogris, Cristina ^a   Rossini, Anna ^c   Ciravolo, Valentina ^c   Castagnoli, Lorenzo ^c   Tagliabue, Elda ^c   Pupa, Serenella M ^c   Musiani, Piero ^b   Monaci, Paolo ^a   Menard, Sylvie ^c   Amici, Augusto ^a  

^a UNIVERSITY OF CAMERINO   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIREFLY LUCIFERASE; HOMODIMER; ISOPROTEIN; PROTEIN KINASE P60; DISULFIDE; ERBB2 PROTEIN, MOUSE; HER2 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BREAST ADENOCARCINOMA; BREAST EPITHELIUM; CANCER CELL; CARCINOGENESIS; CELL MEMBRANE; CONTROLLED STUDY; EMBRYO; EXON; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LATENT PERIOD; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; ONCOGENE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; WILD TYPE; ALTERNATIVE RNA SPLICING; ANIMAL; DIMERIZATION; EXPERIMENTAL NEOPLASM; GENETICS; MUTATION; PROMOTER REGION; REPORTER GENE; TUMOR CELL LINE;

ANIMALIA; MOUSE MAMMARY TUMOR VIRUS; MUS; MUS MUSCULUS;

ALTERNATIVE SPLICING; ANIMALS; CELL LINE, TUMOR; DIMERIZATION; DISULFIDES; FEMALE; GENES, REPORTER; HUMANS; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, TRANSGENIC; MUTATION; ONCOGENES; PROMOTER REGIONS, GENETIC; PROTEIN ISOFORMS; RECEPTOR, ERBB-2;

EID: 79955712254     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018727     Document Type: Article

References (21)

1. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, et al. (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712.
2. Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P, (1988) Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54: 105-115.
3. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, et al. (1992) Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A 89: 10578-10582.
4. Siegel PM, Dankort DL, Hardy WR, Muller WJ, (1994) Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. Mol Cell Biol 14: 7068-7077.
5. Piechocki MP, Ho YS, Pilon S, Wei WZ, (2003) Human ErbB-2 (Her-2) transgenic mice: a model system for testing Her-2 based vaccines. J Immunol 171: 5787-5794.
6. Finkle D, Quan ZR, Asghari V, Kloss J, Ghaboosi N, et al. (2004) HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice. Clin Cancer Res 10: 2499-2511.
7. Pedersen K, Angelini PD, Laos S, Bach-Faig A, Cunningham MP, et al. (2009) A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis. Mol Cell Biol 29: 3319-3331.
8. Kwong KY, Hung MC, (1998) A novel splice variant of HER2 with increased transformation activity. Mol Carcinog 23: 62-68.
9. Siegel PM, Ryan ED, Cardiff RD, Muller WJ, (1999) Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J 18: 2149-2164.
10. Mitra D, Brumlik MJ, Okamgba SU, Zhu Y, Duplessis TT, et al. (2009) An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance. Mol Cancer Ther 8: 2152-2162.
11. Castiglioni F, Tagliabue E, Campiglio M, Pupa SM, Balsari A, et al. (2006) Role of exon-16-deleted HER2 in breast carcinomas. Endocr Relat Cancer 13: 221-232.
12. Guy CT, Cardiff RD, Muller WJ, (1996) Activated neu induces rapid tumor progression. J Biol Chem 271: 7673-7678.
13. Silva CM, (2004) Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene 23: 8017-8023.
14. Taketo M, Schroeder AC, Mobraaten LE, Gunning KB, Hanten G, et al. (1991) FVB/N: an inbred mouse strain preferable for transgenic analyses. Proc Natl Acad Sci U S A 88: 2065-2069.
15. Hogan BCF, Lacy E, (1986) Manipulating the mouse embryo: a laboratory manual.; Press CSHL, editor.
16. Bryda EC, Bauer BA, A restriction enzyme-PCR-based technique to determine transgene insertion sites. Methods Mol Biol 597: 287-299.
17. Bryda EC, Pearson M, Agca Y, Bauer BA, (2006) Method for detection and identification of multiple chromosomal integration sites in transgenic animals created with lentivirus. Biotechniques 41: 715-719.
18. Shepherd CT, Moran Lauter AN, Scott MP, (2009) Determination of transgene copy number by real-time quantitative PCR. Methods Mol Biol 526: 129-134.
19. Zatyka M, Ricketts C, da Silva Xavier G, Minton J, Fenton S, et al. (2008) Sodium-potassium ATPase 1 subunit is a molecular partner of Wolframin, an endoplasmic reticulum protein involved in ER stress. Hum Mol Genet 17: 190-200.
20. Rocuts F, Ma Y, Zhang X, Gao W, Yue Y, et al. (2010) Carbon monoxide suppresses membrane expression of TLR4 via myeloid differentiation factor-2 in betaTC3 cells. J Immunol 185: 2134-2139.
21. Street SE, Zerafa N, Iezzi M, Westwood JA, Stagg J, et al. (2007) Host perforin reduces tumor number but does not increase survival in oncogene-driven mammary adenocarcinoma. Cancer Res 67: 5454-5460.